An mRNA assay system demonstrates proteasomal-specific degradation contributes to cardiomyopathic phospholamban null mutation
Rohner E, Witman N, Sohlmer J, De Genst E, Louch W, Sahara M, Chien K. An mRNA assay system demonstrates proteasomal-specific degradation contributes to cardiomyopathic phospholamban null mutation. Molecular Medicine 2021, 27: 102. PMID: 34496741, PMCID: PMC8425124, DOI: 10.1186/s10020-021-00362-8.Peer-Reviewed Original ResearchConceptsNull mutationMolecular pathwaysProtein analysis toolsBulk RNA sequencingRNA sequencing analysisWild-type reporterDetailed molecular pathwaysDistinct transcriptomic signaturesTranscriptional profilingRNA sequencingProteasomal pathwayHuman embryonic stem cell-derived cardiomyocytesEmbryonic stem cell-derived cardiomyocytesProtein expression levelsProteasomal inhibitionChemical inhibitorsDetectable proteinTranscriptomic signaturesSequencing analysisDegradation contributesMRNA constructsStem cell-derived cardiomyocytesPLN proteinExpression levelsDegradation pathway